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Prostasin is a serine protease present in mammalian urine that increases the activity of the
epithelial sodium channel (ENaC) when the two are coexpressed in Xenopus oocytes. To
determine if aldosterone, one of the principal regulators of urinary Na reabsorption by the
distal nephron, affects prostasin expression, we examined prostasin mRNA and protein in a
cultured mouse cortical collecting duct cell line (M-1), whole rats, and patients with primary
aldosteronism. Aldosterone treatment of M-1 cells substantially increased prostasin
expression and stimulated 22Na uptake. Urinary excretion of prostasin in rats that were
infused with aldosterone likwise increased by ~4-fold when compared with the vehicleinfused rats. Finally, urinary excretion of prostasin in patients with primary aldosteronism
was substantially increased when compared with normal patients. Adrenalectomy reduced
urinary prostasin excretion to control levels, whereas urinary prostasin levels were not
altered in patients undergoing surgery for other reasons. In patients with primary
aldosteronism, reduction in the urinary excretion of prostasin correlated with the increase in
the urinary Na/K ratio. These findings, together with our previous report that prostasin
activates the amiloride-sensitive Na currents through ENaC, demonstrate that prostasin
regulates Na balance in vivo by virtue of its heightened expression in the presence of
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Prostasin is a serine protease present in mammalian urine that increases the activity of the epithelial
sodium channel (ENaC) when the two are coexpressed in Xenopus oocytes. To determine if aldosterone, one of the principal regulators of urinary Na reabsorption by the distal nephron, affects
prostasin expression, we examined prostasin mRNA and protein in a cultured mouse cortical collecting duct cell line (M-1), whole rats, and patients with primary aldosteronism. Aldosterone treatment of M-1 cells substantially increased prostasin expression and stimulated 22Na uptake. Urinary
excretion of prostasin in rats that were infused with aldosterone likwise increased by ∼4-fold when
compared with the vehicle-infused rats. Finally, urinary excretion of prostasin in patients with primary aldosteronism was substantially increased when compared with normal patients. Adrenalectomy reduced urinary prostasin excretion to control levels, whereas urinary prostasin levels were not
altered in patients undergoing surgery for other reasons. In patients with primary aldosteronism,
reduction in the urinary excretion of prostasin correlated with the increase in the urinary Na/K ratio.
These findings, together with our previous report that prostasin activates the amiloride-sensitive Na
currents through ENaC, demonstrate that prostasin regulates Na balance in vivo by virtue of its
heightened expression in the presence of aldosterone.
J. Clin. Invest. 109:401–408 (2002). DOI:10.1172/JCI200213229.

Introduction
Aldosterone is the primary hormone that regulates Na
balance, extracellular fluid volume, and blood pressure
(1–3). Aldosterone increases the rate of Na reabsorption across epithelia at the distal nephron, the distal
colon, and the ducts of exocrine glands by increasing
Na transport through the epithelial Na channel
(ENaC), one of the principal physiologic targets of
aldosterone (4, 5). Regulation of ENaC by aldosterone
has been extensively studied in the A6 renal cell line (6).
In A6 cells, the effect of aldosterone on ENaC is characterized by a three-phase response: (a) a latent period,
lasting 45 minutes; (b) an early response, lasting about
3 hours, in which Na transport increases and the
transepithelial electrical resistance falls; and (c) a late
response, lasting 12 to 24 hours, during which Na
transport further increases while transepithelial resistance does not change significantly. The early and late
effects of aldosterone appear to be mediated by transcriptional mechanisms because actinomycin D fully
inhibits both actions (7). In addition to transcriptional regulation, May et al. reported that aldosterone
increases the rate of de novo synthesis of ENaC α subunit 60 minutes after treatment, raising the possibility
that aldosterone may exert its early phase action on
ENaC through translational mechanisms (6). FurtherThe Journal of Clinical Investigation
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more, Weisz et al. reported the importance of aldosterone-induced trafficking and turnover of individual
ENaC subunits in A6 cells (8). They demonstrated that
long-term treatment with aldosterone stimulated Na
influx by the selective insertion of βENaC at the apical
membrane of A6 cells.
In 1997, a novel mechanism by which serine proteases
regulate ENaC activity was identified. Vallet et al. cloned
a new serine protease, xCAP-1, from A6 cells (9, 10). They
showed that coexpression of xCAP-1 and ENaC in Xenopus oocytes increased the amiloride-sensitive Na current
(INa) by two- to threefold. Chraïbi et al. also reported that
low concentrations of trypsin (2 µg/ml) increased INa by
two- to fivefold in oocytes expressing ENaC (11). The
precise molecular mechanisms of activation of ENaC by
serine proteases are not fully understood. Vuagniaux et
al. isolated a cDNA clone of mCAP-1 from a mouse cortical collecting duct (CCD) cell line and suggested that
CAP-1 is an orthologous gene for prostasin (12). They
also demonstrated that mCAP-1/prostasin activates
ENaC when expressed in oocytes. Recently, we isolated
a cDNA clone of rat prostasin, a serine protease that is
expressed in the same epithelial tissues as ENaC, from
the rat kidney (13). We demonstrated that prostasin is
expressed in rat kidney collecting ducts and that coexpression of rat prostasin with rat ENaC increased INa
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two- to threefold in Xenopus oocytes. We proposed that
prostasin might play an important role in Na handling
in the kidney by activating ENaC. However, regulation
of prostasin mRNA, protein, or activity by physiologic
stimuli, or under pathophysiologic conditions, is not yet
established. Therefore, we investigated the regulation of
prostasin expression by aldosterone because aldosterone
is one of the principal regulators of Na reabsorption in
the distal nephron.
We found that treatment of a mouse CCD cell line
with aldosterone increased the secretion of prostasin
protein into culture media and that aldosterone stimulated 22Na uptake by increasing prostasin expression.
We also found that increased aldosterone levels in rats
markedly increased the urinary excretion of prostasin.
Furthermore, we demonstrated that the urinary excretion of prostasin was substantially increased in patients
with primary aldosteronism and that adrenalectomy
significantly reduced urinary prostasin excretion.
These results indicate that prostasin is an important
physiologic regulator of Na handling in the kidney.

Methods
Cloning of mouse prostasin cDNA. A partial cDNA fragment of mouse prostasin was obtained by PCR with two
degenerate primers that correspond to amino acid
sequences of human prostasin as described previously
(13–15). A first-strand cDNA was synthesized from
mouse kidney total RNA by the oligo (dT) primer
method and amplified by these primers. The amplified
DNA fragment was subcloned into pGEM-T Easy vector (Promega Corp., Madison, Wisconsin, USA) and
sequenced. The 5′ and 3′ ends of mouse prostasin cDNA
was cloned by the 5′ and 3′ rapid amplification of cDNA
ends (RACE) system (Life Technologies Inc., Rockville,
Maryland, USA), following the manufacturer’s protocol. Briefly, mouse kidney total RNA was reverse-transcribed with antisense primer 5A-m1 (5′-CCCAACTCACAATGCCTGCCAA-3′) for the 5′-RACE reaction. The
cDNA that was generated was amplified by nested antisense primers, 5A-m2 (5′-ACCCTGGCAGGCATCCTTGC3′) and 5A-m3 (5′-CGGCTGATGAGTGGTACCTC-3′),
sequentially with the abridged anchor primer and the
abridged universal amplification primer (AUAP). For
the 3′ RACE reaction, total RNA was reverse-transcribed
and amplified by nested PCR with two sense primers,
3S-m1 (5′-GAGGTACCACTCATCAGCCG-3′) and 3S-m2
(5′-GGCCCACTCTCTTGTCCCAT-3′), and the AUAP
primer. Both 5′ and 3′ RACE products were subcloned
into pGEM-T Easy vector and sequenced. A full-length
mouse prostasin cDNA was obtained by ligating the 5′
cDNA end, the partial cDNA fragment, and the 3′
cDNA end. The nucleotide sequence (mouse prostasin
cDNA) reported in this paper has been submitted to the
Genbank/EMBL/DDBJ Data Bank with accession number AB038244.
Cell culture. M-1 cells, an SV40-transformed mouse
CCD cell line, were obtained from the American Type
Culture Collection (Rockville, Maryland, USA). Cells
402
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were maintained in DMEM/Ham’s F-12 (1:1) mixture
(Life Technologies Inc.) supplemented with 5% FBS and
100 nM dexamethasone in a humidified incubator at
37°C and 5% CO2. Experiments were performed when
cells were confluent. Serum and dexamethasone were
removed 48 hours before experiments. All studies
described in this paper were performed on cells between
the 5th and 20th passages.
Northern blot analysis. Total RNA from M-1 cells grown
in 10-cm plastic dishes under experimental conditions
was isolated by using an RNeasy kit (QIAGEN GmbH,
Hilden, Germany). Total RNA (20 µg) of each sample
was resolved on agarose-formaldehyde gels and transferred onto nylon membranes. A full-length cDNA of
mouse prostasin and rat β-actin was individually
labeled with [α-32P] dCTP, and probes were hybridized
with the membranes as described previously (13).
Preparation of proteins and TCA precipitation. After incubation under experimental conditions, culture medium
(10 ml/10-cm dish) was collected and centrifuged at
1,200 g to pellet cell debris. Total protein in the culture
media was precipitated by trichloroacetic acid (TCA)
(final concentration: 15%). The samples were centrifuged
at 12,000 g, and the pellets were washed three times with
ice-cold 80% acetone. The precipitated proteins were
dried and solubilized at 100°C for 5 minutes in 1× TCA
buffer (200 mM unbuffered Tris, 1% SDS, 10% glycerol,
1% β-mercaptoethanol). For preparation of membrane
and cytosolic fractions of M-1 cells, confluent M-1 cells
were washed twice in PBS, scraped into lysis buffer (25
mM Tris-HCl, pH 7.5, 4 µg/ml aprotinin, 4 µg/ml leupeptin, 1 mM PMSF, and 4 µg/ml pepstatin A), and lysed
in a glass Dounce homogenizer. The homogenate was
centrifuged at 800 g to remove nuclei, and the supernatant was centrifuged at 12,000 g to separate the membrane and cytosolic fractions. The membrane fraction
was then dissolved in RIPA buffer (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1%
vol/vol Triton-X 100, 2 mM EDTA, 4 µg/ml aprotinin, 4
µg/ml leupeptin, 1 mM PMSF, and 4 µg/ml pepstatin A).
All these procedures were performed at 4°C.
Immunoblotting. Samples were resolved on 12% SDSPAGE and transferred onto nitrocellulose filters. After
blocking with 5 g/dl nonfat dry milk, the blots were
probed with a polyclonal Ab against prostasin (15) in
Tris-buffered saline with 0.05% Tween-20 for 1 hour,
followed by a secondary Ab (goat anti-rabbit IgG conjugated with horseradish peroxidase) for 1 hour at
room temperature. Bands were visualized using
chemiluminescence substrate (ECL; Amersham Pharmacia Biotech, Amersham, United Kingdom) followed by exposure to x-ray film. The band densities
were quantitated by densitometry (Densitograph 4.0;
ATTO Co., Tokyo, Japan).
22Na influx studies. The activities of ENaC in M-1 cells
were determined by measurement of amiloride-sensitive
22Na uptake (16). Preliminary experiments determined
that amiloride-sensitive uptake of 22Na was linear for up
to 15 minutes. After incubation under experimental con-
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ditions, cells on six-well dishes were rinsed twice and
preincubated for 15 minutes at 37°C in a Na-free solution composed of 137 mM N-methylglucamine
(NMDG), 5.4 mM KCl, 1.2 mM MgSO4, 2.8 mM CaCl2,
and 15 mM HEPES (pH 7.4). At the end of the preincubation, the Na-free solution was replaced by the uptake
solution composed of 14 mM NaCl, 35 mM KCl, 96 mM
NMDG, and 20 mM HEPES (pH 7.4) containing 1 mM
ouabain and 1.5 µCi/ml of 22NaCl (specific activity: 748
µCi/mg Na; New England Nuclear, Boston, Massachusetts, USA) in the presence or absence of 1 mM amiloride.
After a 5-minute incubation, uptake was stopped by
washing the cells four times with 1 ml/well of an ice-cold
solution containing 120 mM NMDG and 20 mM
HEPES (pH 7.4). The cells were then solubilized in 0.5%
Triton X-100. Tracer activities were measured in a gamma
scintillation counter. The amount of protein per well was
measured using the BCA kit (Pierce Chemical Co., Rockford, Illinois, USA). All assays were performed in duplicate. ENaC activity was determined as the difference
between 22Na uptake in the presence or absence of
amiloride. The results were normalized for protein concentration and expressed as percentage of control.
Aldosterone infusion studies. Experiments were conducted
in male Sprague-Dawley rats (160∼170 g) from Charles
River Laboratories (Wilmington, Massachusetts, USA).
Rats were anesthetized with pentobarbital sodium
(Nembutal; Abbot Laboratories, North Chicago, Illinois,
USA) before subcutaneous implantation of osmotic
minipumps (model 2001; Alza Corp., Palo Alto, California, USA) that delivered 100 µg/100 g body weight aldosterone per day (17). Aldosterone (Sigma Chemical Co., St.
Louis, Missouri, USA) was dissolved in DMSO and diluted with isotonic saline. Control rats received vehicle
alone. All rats were kept in metabolic cages, and 24-hour
urine collections were made. Urine samples, corrected for
creatinine excretion, were concentrated by TCA precipitation, and the amount of prostasin was determined by
immunoblotting as described above. Blood samples were
obtained at the end of the experiments to measure plasma aldosterone, serum potassium, and serum bicarbonate concentrations. All animal procedures were approved
by the institutional ethics committee.
Patients with primary aldosteronism. Three patients with
primary aldosteronism and three patients undergoing
surgery for other reasons with general anesthesia were
enrolled in the study. Institutional approval was
received from the Kumamoto University Human Subject Review Board, and written informed consent was
obtained from each patient prior to the studies. All
patients with primary aldosteronism were treated with
adrenalectomy, and 24-hour urine collections were
obtained before and after surgery. The prostasin excretion level in urine samples was determined by the same
method as described above.

Results
Cloning of full-length mouse prostasin cDNA. To evaluate
the level of prostasin mRNA expression in the M-1 cell
The Journal of Clinical Investigation
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line by Northern blotting, we isolated a full-length
prostasin cDNA from mouse kidney using RT-PCR, 5′
and 3′ RACE methods. The prostasin cDNA encodes a
339–amino acid polypeptide, including a 29–amino
acid signal peptide, a 15–amino acid light chain, and a
295–amino acid heavy chain. The catalytic triad that is
highly conserved among the serine proteases is also
found in mouse prostasin (His85, Asp134, and Ser238).
Vuagniaux et al. proposed that mCAP-1, xCAP-1, and
human prostasin are orthologous genes (12). Our
cloning of mouse prostasin cDNA also revealed that
mouse prostasin is identical to the mCAP-1 at the
amino acid level.
Effect of aldosterone on prostasin expression in M-1 cells. Previously, we demonstrated that expression of prostasin
stimulates ENaC in Xenopus oocytes (13). May et al. also
reported that aldosterone increases ENaC activity as
well as ENaC protein translation in A6 cells (6). These
findings motivated us to study the effect of aldosterone
on the expression of prostasin. We used M-1 cells to
study the regulation of prostasin by aldosterone
because both prostasin and ENaC are expressed in the
CCD segment (12, 13, 18) and aldosterone modulates
Na transport in M-1 cells (19). We measured prostasin
mRNA abundance in M-1 cells following aldosterone
treatment. Figure 1 shows the time course of prostasin
mRNA induction by aldosterone. Prostasin transcripts
were readily detected under basal conditions. Aldosterone induced an increase in prostasin mRNA after 6
hours of stimulation. Maximum induction occurred at
24 hours (1.9-fold ± 0.2-fold), and elevated mRNA levels were still present for up to 48 hours.
We then determined the distribution of prostasin
protein between M-1 cell membranes and cytosol.
Based on its predicted secondary structure, prostasin is
presumed to be a secreted and/or a glycosylphosphatidylinositol-anchored protein, so we also determined if it was present in cell culture medium. Proteins
in the membrane and cytosolic fractions of M-1 cells
and culture media were precipitated by TCA and subjected to immunoblotting. As shown in Figure 2a, the
antiprostasin Ab detected a single band of 40 kDa only
in the culture media under reducing conditions. The
band was barely detectable in either the membrane or
cytosolic fractions (left panel). The 40-kDa band was
completely blocked by the incubation of Ab with the
synthetic prostasin peptide used for immunization,
demonstrating the specificity of the immunodetection
(Figure 2a, right panel). We could not detect prostasin
protein in the membrane or cytosolic fractions even
when we immunoblotted 80 µg of protein. While
prostasin protein was shown to be secreted when synthesized in the prostate (15), recent findings also indicated that it can assume a membrane-anchored form
via glycosylphosphatidylinositol in prostate epithelial
cells that naturally express prostasin (20). In the M-1
cells, it is possible that the distribution of the membrane-anchored versus the secreted prostasin protein
for the total pool of prostasin protein synthesized is
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Figure 1
Effect of aldosterone on the expression of prostasin mRNA in M-1
cells. M-1 cells, which were serum deprived for 48 hours, were treated
with 1 µM aldosterone and harvested at various time points (0, 6, 12,
24, and 48 hours) for isolation of total RNA. Each lane contains 20 µg
of total RNA. The abundance of prostasin mRNA was normalized for
β-actin (bottom). Aldosterone induced an increase in prostasin mRNA
after 6 hours of stimulation. Maximum induction occurred at 24 hours
(1.9-fold ± 0.2-fold increase), and this effect was observed for up to
48 hours. This blot is representative of four separate experiments. Values are mean ± SEM (n = 4). *P < 0.02.

different from that in the prostate cells. We speculate
that prostasin is synthesized as a membrane protein
that is quickly cleaved by some mechanism and
released into the extracellular medium. Consequently,
in subsequent studies, we analyzed expression of
prostasin protein in the culture media of M-1 cells. Figure 2b shows that treatment with aldosterone
increased the expression of prostasin protein by 3.5fold ± 0.6-fold and 3.3-fold ± 0.3-fold when compared
with the controls during 24-hour and 48-hour incubations. This stimulatory effect of aldosterone on
prostasin protein expression was dose dependent over
the range 0–10-6 M (Figure 3c). Even after treatment
with aldosterone, we could not detect prostasin protein
in either membrane or cytosolic fractions (data not
shown). These findings demonstrate that aldosterone
stimulates expression of prostasin at the levels of
mRNA as well as protein in M-1 cells.
Effect of aprotinin on aldosterone-induced 22Na uptake in
M-1 cells. To determine if the aldosterone-induced
increase in prostasin protein abundance in M-1 cells
indeed has a role in activating ENaC, we measured
amiloride-sensitive 22Na uptake. M-1 cells were treated
for 24 hours with 1 µM aldosterone or vehicle in the

presence or absence of 28 µg/ml aprotinin, a potent
prostasin inhibitor (IC50 of aprotinin for prostasin is
11.7 ng/ml) (15), and then amiloride-sensitive 22Na
uptake was measured. As shown in Figure 3a, treatment with aprotinin decreased the amiloride-sensitive
22Na uptake by 25% ± 9% under basal conditions.
Nakhoul et al. reported that aprotinin reduced the Isc
in M-1 cells by 49% ± 9% (19). The difference in the
magnitude of the aprotinin-sensitive component in the
basal Na current in M-1 cells could have resulted from
the differences of the methods used. Aldosterone
increased the 22Na uptake by 189% ± 25%, and aprotinin significantly reduced the Na influx in aldosterone-treated cells. Interestingly, aprotinin-sensitive
Na uptake was markedly increased by twofold in aldosterone-treated cells when compared with the control.
Also, aldosterone increased the aprotinin-insensitive
component. To address the question if sufficient

Figure 2
Effect of aldosterone on the expression of prostasin protein in M-1
cells. (a) Cellular distribution of prostasin protein in M-1 cells. Forty
micrograms of membrane and cytosolic proteins as well as 3 ml of
TCA-precipitated culture medium from M-1 cells were subjected to
SDS-PAGE. Blots were probed with the antiprostasin Ab and with Ab
preadsorbed with the immunizing peptide. Prostasin was detected as
a 40-kDa band in the culture medium only. (b) Effect of aldosterone
on the expression of prostasin protein in M-1 cells. M-1 cells were
treated with 1 µM aldosterone or vehicle for 24 and 48 hours. Proteins
in the culture medium were TCA precipitated and subjected to SDSPAGE. Treatment with 1 µM aldosterone increased prostasin protein
expression by 3.5-fold ± 0.6-fold (for 24 hours) and 3.3-fold ± 0.3fold (for 48 hours) when compared with the corresponding controls.
This blot is representative of five separate experiments. Aldo, aldosterone; cont, control. Values are mean ± SEM (n = 5). (c) Dose
dependence of aldosterone effect on prostasin. M-1 cells were treated with increasing concentrations of aldosterone (0, 10–8, 10–7, and
10–6 M) for 24 hours. The expression level of prostasin in the culture
media was determined by immunoblotting. The stimulatory effect of
aldosterone on prostasin protein expression was dose dependent over
the range of 0–10–6 M. This blot is representative of five separate experiments. Values are mean ± SEM (n = 5). *P < 0.001, **P < 0.02.
404
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Figure 3
Role of prostasin in the aldosterone-induced increase in 22Na uptake in
M-1 cells. (a) Effect of aprotinin on aldosterone-induced 22Na uptake
in M-1 cells.M-1 cells were treated with 1 µM aldosterone or vehicle for
24 hours in the presence or absence of 28 µg/ml aprotinin. Amiloridesensitive 22Na uptake was determined in the presence of 1 mM
amiloride and 1 mM ouabain. Treatment with aprotinin partially inhibited the basal Na influx as well as the aldosterone-induced Na influx.
Aldosterone significantly increased the aprotinin-sensitive Na uptake
twofold. Apro, aprotinin. Values are mean ± SEM (n = 6). (b) Effect of
recombinant prostasin on aldosterone-induced 22Na uptake in M-1
cells. M-1 cells were treated with 1 µM aldosterone or vehicle for 24
hours, then cells were treated with 2 µg/ml of recombinant prostasin.
Amiloride-sensitive 22Na uptake was determined as described above.
Treatment with recombinant prostasin further increased the basal Na
influx as well as the aldosterone-induced Na influx (1.35-fold and
1.56-fold, respectively). Values are mean ± SEM (n = 7). *P < 0.05.

prostasin might be present in the culture media under
basal conditions to activate ENaC, and if an aldosterone-mediated increase in prostasin secretion into
culture media might have a minimal effect on further
enhancing ENaC activity, we treated M-1 cells with
purified recombinant prostasin (20) in the presence or
absence of aldosterone and measured the amiloridesensitive 22Na uptake. Figure 3b shows that the addition of recombinant prostasin further increased the
22Na uptake by 1.35-fold in control cells and by 1.56fold in aldosterone-treated cells, suggesting that ENaC
expressed on the apical membrane of M-1 cells are not
fully activated by prostasin under basal conditions and
that an aldosterone-induced increase in the prostasin
abundance in the culture media has a definite role in
the activation of ENaC. These results, taken together
The Journal of Clinical Investigation
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with the findings that aldosterone increases prostasin
protein expression in M-1 cells, demonstrate that M-1
cells have aprotinin-sensitive Na uptake under basal
conditions that is probably due to prostasin expression
and that aldosterone substantially increases the
prostasin-dependent Na uptake by increasing prostasin
protein abundance. Furthermore, these findings
strongly support our hypothesis that aldosteroneinduced increase in prostasin protein has a key role in
the aldosterone-induced activation of ENaC.
Effect of amiloride on aldosterone-induced prostasin expression in M-1 cells. Aldosterone activates Na transport in
M-1 cells (19) and distal tubules of other species (2)
through activation of ENaC. Prostasin expression
could be increased by mechanisms that are a consequence of activation of ENaC, such as an increase in
the intracellular Na concentration. To determine
whether an increase in prostasin expression is secondary to an event following the activation of ENaC by
aldosterone, we studied the effect of amiloride, a
potent ENaC inhibitor, on the aldosterone-induced
increase in prostasin expression in the cell culture
media. M-1 cells were preincubated with 5 µM
amiloride for 30 minutes, and then aldosterone (final
1 µM) was added to the media in the presence of
amiloride. Twenty-four hours after incubation, medium was collected and subjected to immunoblotting.
As shown in Figure 4, amiloride treatment had no
effect on either basal or aldosterone-induced prostasin
protein expression. These results suggest that the
induction of prostasin by aldosterone is not mediated
by an amiloride-sensitive mechanism that is secondary
to ENaC activation. We then studied the effect of
prostasin on the amiloride sensitivity of ENaC. The
Kiamil of ENaC in the absence of prostasin (0.10 ± 0.006
µM; n = 12) did not significantly differ from the Kiamil
in the presence of prostasin (0.094 ± 0.005 µM; n = 14).
Aldosterone-infusion studies. To study the stimulatory
effect of aldosterone on prostasin expression in vivo,
we infused rats with aldosterone through subcuta-

Figure 4
Effect of amiloride on aldosterone-induced expression of prostasin
protein in M-1 cells. M-1 cells were treated with 1 µM aldosterone
or vehicle in the presence or absence of 5 µM amiloride for 24 hours.
Prostasin protein abundance was determined by immunoblotting.
Treatment of M-1 cells with amiloride had no effect on the secretion
of prostasin in the culture media (aldosterone: 1.9-fold ± 0.2-fold,
aldosterone + amiloride: 1.8-fold ± 0.7-fold, not significant). This
figure is representative of four separate experiments. Am, amiloride.
Values are mean ± SEM (n = 4). NS, not significant; *P < 0.02.
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Figure 5
Effect of aldosterone infusion on prostasin excretion in the urine.
Immunoblot showing the effect of aldosterone infusion (100 µg/100
g body weight/day) for 7 days on the abundance of prostasin excreted into rat urine. Urine samples that are equivalent to 80 µg creatinine excretion were TCA precipitated, and urinary prostasin excretion was determined by immunoblotting. Aldosterone infusion
resulted in a substantial increase in prostasin excretion into the urine.
The effect of aldosterone was time dependent, and maximum induction was observed at day 7 (4.3-fold ± 2.0-fold increase over control). This figure is representative of five separate experiments. Values are mean ± SEM (n = 5). *P < 0.004.

neously implanted osmotic minipumps for 7 days.
Plasma aldosterone levels were significantly increased
in aldosterone-infused rats (control: 134 ± 23 pg/ml,
n = 5, and aldosterone: 3,425 ± 354 pg/ml, n = 5,
P < 0.05). The aldosterone-treated rats also exhibited
hypertension (control: 111 ± 5 mmHg, n = 5, and
aldosterone: 127 ± 2 mmHg, n = 5, P < 0.05),
hypokalemia (control: 5.0 ± 0.2 mEq/l, n = 5, and
aldosterone: 3.3 ± 0.8 mEq/l, n = 5, P < 0.05), and
metabolic alkalosis (control: 27.0 HCO3 ± 1.9 mEq/l,
n = 5, and aldosterone: HCO3 41.3 ± 1.7 mEq/l, n = 5,
P < 0.05) 7 days after pump implantation. There was
not any significant difference in the body weight
between control rats and aldosterone-treated rats
(control: 220 ± 6 g, n = 5, and aldosterone: 215 ± 5 g,
n = 5, P = not significant). We could not detect
prostasin expression by immunoblotting membrane
or cytosolic fractions of rat kidney cortex and medulla with or without aldosterone infusion (data not
shown). However, we easily detected prostasin in rat
urine under basal conditions. These data suggest that
prostasin is released from the apical membrane of
kidney tubules by some mechanisms in rats as well as
in the mouse CCD cell line. As shown in Figure 5,

aldosterone infusion resulted in a substantial increase
in prostasin excretion into the urine. The effect of
aldosterone was time dependent, and the maximum
induction was observed at day 7 (4.3-fold ± 2.0-fold
increase over control). These findings indicate that
aldosterone induces prostasin expression in the kidney in whole animals as well as in cultured cells and
that it may play an important role in the impaired Na
handling in patients with hyperaldosteronism.
Urinary prostasin levels in patients with primary aldosteronism. To determine whether aldosterone increases prostasin protein expression in humans, we measured urinary prostasin protein expression in patients
with primary aldosteronism before and after adrenalectomy. The diagnosis of an aldosterone-secreting
adrenal adenoma was made on the basis of measurement of plasma renin activity and plasma aldosterone levels and by radiologic examinations, including computed tomography and magnetic resonance
imaging scans. Patient profiles, plasma renin activities, plasma aldosterone concentration (PAC), and
serum potassium levels of the patients are shown in
Table 1. To study urinary prostasin excretion, 24hour urine collections were obtained before and 7
days after adrenalectomy. Figure 6a shows the results
of Western blot analysis of urinary prostasin excretion before and after adrenalectomy from patient
number 1. Adrenalectomy resulted in a marked
decrease in urinary prostasin protein abundance.
PAC was also reduced to the normal range after the
operation (Table 1). Interestingly, the urinary Na/K
ratio correlated with the expression level of prostasin,
suggesting that aldosterone-induced prostasin plays
a role in activation of ENaC (Figure 6a). Patients with
high PAC level (numbers 1–3) had substantially higher urinary prostasin excretion when compared with
normal PAC level patients (numbers 4–6) (Figure 6b).
In all three patients with primary aldosteronism,
adrenalectomy resulted in a significant decrease in
the urinary prostasin excretion, while no change in
urinary prostasin excretion was observed in the three
patients with normal PAC levels (Figure 6b). These
results indicate that prostasin is regulated by aldosterone in humans as well as in rats.

Table 1
Clinical profiles of the patients with primary aldosteronism and other diseases
Patients

1
2
3
4
5
6

Sex

Age
(years old)

Height
(cm)

BW
(kg)

PRA
(ng/ml/h)
before/after

PAC
(pg/ml)
before/after

p-K
(mEq/l)

Diseases

Male
Female
Female
Male
Female
Male

22
51
43
26
51
37

175
155
160
171
151
178

69.6
51.1
57.6
89.0
45.0
92.5

<0.1/0.1
<0.1/0.2
<0.1/0.1
0.6/0.5
0.5/0.2
1.8/1.3

330/50
189/51
778/34
80/58
91/49
94/110

2.8
3.2
2.0
4.2
3.9
4.2

PA
PA
PA
Achalasia
PHP
Cholelithiasis

Values are mean ± SEM. Plasma renin activities PRA and PAC were measured before and 7 days after the operation in each patient. BW, body weight; p-K,
serum potassium; PA, primary aldosteronism; PHP, primary hyperparathyroidism, PRA, plasma renin activities.
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Figure 6
Urinary prostasin levels in patients with primary aldosteronism and
control patients. (a) Time course of urinary prostasin expression in
patients with primary aldosteronism (patient 1) before and after the
adrenalectomy. Sample volumes were adjusted to be equivalent to
750 µg creatinine excretion, and urinary excretion of prostasin was
determined by the immunoblotting. Urinary Na/K ratio is shown at
the bottom. (b) Urinary prostasin excretion in two other independent patients with primary aldosteronism (patients 2 and 3) and in
three other independent patients with normal PAC level who had the
surgery for other reasons (patients 4, 5, and 6). Twenty-four–hour
urine collections were made before and 7 days after surgery. The urinary excretion of prostasin was determined by immunoblotting as
described above. Pt, patient.

Discussion
Serine proteases such as CAP-1, trypsin, and chymotrypsin have been shown to stimulate INa in Xenopus
oocytes expressing ENaC, although the precise mechanisms of activation are not known (10–12). We cloned
a rat prostasin cDNA and demonstrated that expression of rat prostasin increased the Na current through
ENaC (13). Prostasin is expressed in epithelial tissues
that are known to be the sites of amiloride-sensitive
transepithelial Na transport. Therefore, we hypothesized that prostasin may play an important role in Na
handling by the kidney through the activation of
ENaC. In the present studies, we addressed the question of whether aldosterone, a major natriferic hormone that increases Na uptake in the distal nephron by
activation of ENaC, could regulate the expression of
prostasin in mammals. We showed that aldosterone
stimulates Na uptake by increasing the expression of
prostasin mRNA and protein in cultured mouse CCD
cells. We also showed that urinary excretion of
prostasin is increased in aldosterone-infused rats and
in patients with primary aldosteronism.
Regulation of prostasin by aldosterone. In the study presented here, we showed that aldosterone induces a
twofold increase in prostasin mRNA in M-1 cells.
Because we have not yet measured the rate of transcription of this gene, we do not know whether the
increased abundance of mRNA is mediated by a direct
transcriptional effect and/or by an effect on mRNA
turnover. The stimulatory effect of aldosterone on the
The Journal of Clinical Investigation

|

accumulation of prostasin protein in the culture media
or urine was proportional to the effect on mRNA abundance. Aldosterone significantly induced prostasin
excretion in rat and human urine by approximately
twofold. In the current study we have not addressed the
question of whether aldosterone could regulate the
assembly of prostasin in the endoplasmic reticulum, its
transport to the plasma membrane, its release from the
plasma membrane, and the stability of the released protein in the culture media or urine; each step could be
separate sites of hormonal regulation.
Possible involvement of prostasin in aldosterone-induced Na
absorption. Here we demonstrated that treatment of M-1
cells increases aprotinin-sensitive, further, prostasin-sensitive, Na uptake by increasing the prostasin protein
abundance. Until this report, there was no direct evidence showing that serine proteases are involved in Na
reabsorption in the distal nephron. However, data in several papers support the concept that serine proteases
may play a key role in Na uptake in the kidney (9–13).
Nakhoul et al. demonstrated that aprotinin added to the
luminal side of M-1 cells induces a 50% decrease in the
Isc, suggesting that serine proteases such as prostasin
could stimulate ENaC activity since aprotinin is a potent
inhibitor of prostasin activity (19). More recently, Masilamani et al. reported that aldosterone infusion in rats
resulted in a molecular weight shift of γENaC from 85
kDa to 70 kDa (21). They speculated that proteolytic
cleavage of the γENaC by serine proteases such as
CAP-1 might be responsible for this phenomenon. Since
prostasin is expressed in the collecting ducts and is
excreted into urine, it may participate in the molecular
weight shift of γENaC and subsequent activation of
ENaC in mammals. Nafamostat mesilate (NM), a synthetic serine protease inhibitor, inhibits various serine
proteases including trypsin, thrombin, activated factor
X, and activated complement. Although NM has been
shown to be effective in the treatment of pancreatitis and
disseminated intravascular coagulation, it is associated
with hyponatremia and hyperkalemia in some cases (22).
Muto et al. reported that perfusion of rabbit CCD with
NM inhibited INa, resulting in inhibition of potassium
secretion (23, 24). They suggested that hyponatremia
and/or hyperkalemia associated with NM treatment
could be caused in part by inhibition of amiloride-sensitive Na conductance. This finding also implies physiologic involvement of serine proteases such as prostasin
in Na handling in renal tubules.
Aldosterone stimulates Na reabsorption by multiple
actions on multiple proteins involved in Na transport
or its regulation. Aldosterone stimulates the transcription of ENaC in the kidney and increases the
channel number at the apical membrane of the collecting duct, leading to an enhanced Na reabsorption
in the distal nephron segment. Sgk, a serine/threonine kinase that activates electrogenic Na transport
by increasing the number of Na channels (ENaC) at
the cell surface, is also an aldosterone-induced protein
and may play a key role in the aldosterone-mediated
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regulation of Na absorption (25). Our current study
suggests an additional mechanism by which aldosterone could stimulate Na transport through ENaC
by way of increasing the expression of prostasin in the
kidney. Our results provide a new insight into the
regulation of distal nephron Na transport and pathogenesis of hypertension and provide the rationale for
development of new therapeutic agents for hypertension and Na-retaining states.
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